ClinicaliQ Trial Snapshot
- Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) — Recruiting • Phase II • NCT07062588.
- AGA2115 tested against placebo in adults with osteogenesis imperfecta caused by COL1A1 or COL1A2 gene mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo. Conditions: Osteogenesis Imperfecta (OI) Interventions: AGA2115, Placebo Lead Sponsor: Angitia Incorporated Limited Planned Enrollment: 80 participants